Alejandro Recio Boiles, MD
Hematology-Oncology · Tucson, AZNPI 1104266964
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.9%), food and beverage and education — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Johnson & Johnson at 31.5% of the total. 2025 is the largest year on record at $1,873, 2.5 times the $756 reported in 2019.
Across 51 payments — averaging $92.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$1K
- Janssen Global Services, LLC$1K
- Pfizer$230
- Astellas Pharma US Inc$226
- Sanofi-aventis U.S. LLC$189
- Sumitomo Pharma America, Inc.$189
- plus $1K from 16 others
Across 491 payments — averaging $5049.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$955K
- Merck$827K
- E.r. Squibb & Sons, L.L.C.$199K
- Eli Lilly$176K
- AbbVie$98K
- Pfizer$82K
- plus $143K from 6 others
What the payments were for
- Consulting fees$2,43852%
- Speaking & faculty fees$992%
- Food & beverage$1,70136%
- Education$45610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 3 | $1,479 |
| Janssen Global Services, LLC | 3 | $1,050 |
| Pfizer | 9 | $230 |
| Astellas Pharma US Inc | 6 | $226 |
| Sanofi-aventis U.S. LLC | 2 | $189 |
| Sumitomo Pharma America, Inc. | 2 | $189 |
| Fennec Pharmaceuticals, Inc. | 1 | $152 |
| Gilead(2 entities) | 3 | $143 |
| Incyte Corporation | 3 | $141 |
| Rigel Pharmaceuticals, Inc. | 1 | $123 |
| Jazz Pharmaceuticals Inc. | 1 | $122 |
| Sanofi | 3 | $120 |
| Exelixis Inc. | 1 | $112 |
| Bayer | 4 | $102 |
| Genentech, Inc. | 2 | $83 |
| Caris MPI, Inc. | 1 | $73 |
| Myovant Sciences Inc. | 1 | $60 |
| AVEO Pharmaceuticals, Inc. | 1 | $28 |
| Bristol Myers Squibb | 1 | $22 |
| Genentech USA, Inc. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology-oncology providers in Arizonato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 46 | $1,173,672 |
| Abiraterone Acetate | 229 | $396,191 |
| NubeqaDarolutamide | 29 | $372,007 |
| XtandiEnzalutamide | 27 | $338,592 |
| ErleadaApalutamide | 14 | $196,124 |
| OrgovyxRelugolix | 63 | $162,600 |
| EliquisApixaban | 18 | $22,523 |
| Prednisone | 200 | $823 |
| Ondansetron Hcl | 20 | $429 |
| Tramadol Hcl | 23 | $340 |
| Levothyroxine Sodium | 40 | $305 |
| Gabapentin | 29 | $141 |
| Lisinopril | 16 | $103 |
| Amlodipine Besylate | 12 | $67 |
| MethotrexateMethotrexate Sodium | 12 | $59 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $112 | $1,173,67246 claims |
| BayerNubeqa | $102 | $372,00729 claims |
| Astellas Pharma US IncXtandi | $226 | $338,59227 claims |
| Johnson & JohnsonErleada | $1,479 | $196,12414 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $189 | $162,60063 claims |
| PfizerEliquis | $230 | $22,52318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology-oncology providers in Arizonaon file to place this against a meaningful peer group, so we don't.
Other hematology-oncology in Tucson
- Madappa KundrandaGilbert$71K
- Navjeet GandhokPeoria$19K
- Amol RakkarGlendale$18K
- Valerie IsraelLake Havasu City$4K
- James ChoiGlendale$4K
- Madhuri KadiyalaChandler$865
- Srivyshnavi NarraSun City$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.